Analcid may be part of symptomatic management in situations involving certain distressing symptoms. Its therapeutic scope includes addressing acute symptom patterns.

---

The medication is commonly used to help manage symptoms related to inflammatory or irritative states. The therapeutic scope is relevant for managing symptomatic relief related to mild to moderate acute pain, the intense cramping of primary dysmenorrhea, pain and swelling linked to certain types of arthritis (Osteoarthritis and Rheumatoid Arthritis), and the reduction of fever. The benefit provides support that helps with the overall symptom load during periods of heightened symptoms and offers symptomatic relief.

It is particularly relevant in clinical settings involving symptoms associated with acute or episodic changes, or those symptoms that may create noticeable physiological strain. It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations.

“This approach supports the patient during difficult episodes by easing distress, assisting with maintaining functional stability when symptoms are more noticeable.”

---

Quick Fact: Relief for Episodic Pain The medicine is commonly used when symptoms intensify, such as during episodes of acute dental pain or scenarios where additional management of discomfort is required following an injury.

Who Can and Cannot Use Analcid?

This section details the official population eligibility and non-eligibility rules for Analcid (Mefenamic Acid), based strictly on government regulatory labeling.

Eligibility Scope

Classification	Population/Condition
Use Allowed	Adults and adolescents 14 years of age.
Contraindicated	Patients with known hypersensitivity to NSAIDs, active gastrointestinal (GI) bleeding or ulceration, severe renal/hepatic/cardiac failure, or inflammatory bowel disease.
	Patients in the third trimester of pregnancy (after 30 weeks gestation) and those undergoing Coronary Artery Bypass Graft (CABG) surgery.
Use Restricted	Older adults and patients with mild to moderate organ impairment (renal or hepatic), controlled hypertension, or a history of GI disease.
Not Recommended	Breastfeeding women and women attempting to conceive (may impair fertility).

Age-Related Eligibility

The safety and efficacy of Analcid have not been established in children younger than 14 years of age. In the geriatric population, use requires caution and is typically limited to the lowest effective dose for the shortest possible duration, as noted in official prescribing information.

Analcid Interactions with other medicines and products

Analcid (Mefenamic Acid) has an officially documented interaction profile based on its nonsteroidal anti-inflammatory drug (NSAID) classification and its impact on drug clearance pathways.

Interaction Classifications and Restrictions

Classification	Interacting Agents / Conditions	Constraint Type
Contraindicated	Other NSAIDs or Aspirin (in allergic patients)	Must not be co-administered
Contraindicated	Peri-operative pain in the setting of CABG surgery	Prohibited use for this indication
Exposure-Altering	Lithium, Methotrexate, Digoxin	Increased plasma concentration
Pharmacodynamic	Oral Anticoagulants, SSRIs, Ciclosporin, Tacrolimus	Increased risk of bleeding or nephrotoxicity
Efficacy Reduction	ACE Inhibitors, ARBs, Diuretics	Decreased therapeutic effect of co-administered drug

Officially Documented Interaction Statements

• The systemic exposure of Analcid is increased when co-administered with CYP2C9 Inhibitors (e.g., Fluconazole), a pharmacokinetic interaction documented in regulatory labeling.
• Analcid affects the renal elimination of Lithium and the tubular secretion of Methotrexate, leading to increased plasma concentrations of these substances.
• The co-administration of Analcid with Oral Anticoagulants (e.g., Warfarin) and SSRIs increases the documented risk of serious gastrointestinal bleeding events.
• The risk of acute renal impairment from interactions with blood pressure medications (e.g., ACE Inhibitors, ARBs) or Diuretics is noted to be higher in elderly and volume-depleted patients.

The mechanism of action for Mefenamic Acid (Analcid) is defined by its ability to modulate the eicosanoid pathway and influence neural signaling. The drug primarily functions as a reversible, non-selective inhibitor of the Cyclooxygenase-1 ( COX-1) and Cyclooxygenase-2 ( COX-2) enzymes. This inhibition blocks the synthesis of prostaglandins, lipid mediators that modulate afferent neuron excitability and local vascular responses, thereby modifying early molecular steps that shape systemic physiological outcomes.

The mechanism also engages components of the Central Nervous System (CNS), particularly by reducing prostaglandin levels in the hypothalamus, which reverses the pyrogen-induced alteration of the thermal regulatory set-point. Additionally, Mefenamic Acid affects systems where specific transmitters dominate, such as by modulating GABA-A receptors and blocking certain Transient Receptor Potential (TRP) ion channels, influencing the transmission kinetics of nociceptive signals. This molecular and neural pathway engagement results in defined physiological alterations that modulate the overall pattern of inflammatory and nociceptive pathway activity.

The administration of Analcid (Mefenamic Acid) follows a standardized approach to its use.

Administration Scope

The established route of administration is oral through the use of capsules, tablets, or, in some regions, oral suspension.

The standardized dosing schedule for acute conditions begins with an initial dose of 500 mg, followed by a maintenance dose of 250 mg. This maintenance dose is generally administered at intervals of every 6 hours. For certain conditions in specific regions, the total daily amount may be up to 1500 mg in divided doses.

Use Context and Duration

Analcid is taken with food or milk to ensure proper administration. The duration of treatment is limited for acute symptom management: for acute pain, use generally does not exceed seven days (one week), and for primary dysmenorrhea, use is typically limited to two to three days. The medication is used in patients 14 years of age and older for its primary indications. For all populations, the clinical standard is using the lowest effective dose for the shortest possible duration.

Procedural Structure

The overall use protocol involves starting the regimen with the initial 500 mg dose, proceeding with the 250 mg maintenance dose every six hours, and adhering to the short-term duration limits. This structure establishes Analcid as a short-course therapy administered under specific contextual conditions.

Research evidence / Overview of studies for Analcid

---

Evidence for Use in Primary Dysmenorrhea

Research exploring Analcid (Mefenamic Acid) for menstrual cramping focuses on conditions characterized by fluctuating or episodic manifestations. The primary evidence comes from short-term Randomized Controlled Trials (RCTs) and Crossover Studies, where the agent was compared against an inactive placebo or active comparators. These studies typically included adult women and adolescents. Researchers examined patient-reported outcomes describing perceived discomfort and tracked the frequency of requiring additional pain relievers (rescue medication) during the menstrual cycle. The findings describe patterns observed in the studies regarding pain intensity scores measured during the short-term study period.

---

Evidence for Acute Mild to Moderate Pain Relief

The core evidence consists of single-dose, placebo-controlled RCTs used in studies examining short-term or episodic symptom patterns in models of acute pain. These trials tracked the change in pain intensity and the time elapsed before participants requested supplementary pain medication. Follow-up durations were limited, typically observing effects over just a few hours up to a maximum of seven days of treatment, which means long-term effects are not fully established. Additionally, sample sizes were modest in the specific analysis of this agent within some systematic reviews.

---

Evidence for Pain and Swelling in Arthritic Conditions

Analcid was evaluated in research contexts involving conditions characterized by fluctuating or episodic manifestations, specifically Osteoarthritis and Rheumatoid Arthritis. Evidence includes comparative clinical trials that tracked outcomes reflecting daily functioning and measures of inflammation. Regulatory documentation describes the agent's established identity as a nonsteroidal anti-inflammatory drug studied for addressing these symptoms. However, the evidence primarily contributes to understanding short-term symptom patterns during acute flare-ups, and there is limited information for long-term outcomes regarding disease progression.

---

Research Gaps and What Remains Uncertain

While research contributes to the broader evidence landscape, several limitations are consistently noted. Evidence quality varies across studies, and sample sizes were modest in some key areas. Because the drug is primarily relevant in trials assessing short-term or episodic symptom patterns, the long-term effects are not fully established. Furthermore, data for certain groups remain insufficient, especially for older adults and for patients who have comorbidities. These limitations highlight that research is ongoing and further studies are needed, particularly concerning the chronic use profile.

Key Studies & References

1. Mefenamic Acid: StatPearls [Internet] (Overview of Analgesic and Anti-inflammatory use)
2. IUPHAR/BPS Guide to PHARMACOLOGY (Anthranilic Acid Derivatives/Fenamates classification)

Common questions about Analcid (FAQ)

Q: Is Analcid a brand name or the generic name of the substance?

Analcid is a brand name for this medication. The active ingredient within Analcid is Mefenamic Acid, which is the official generic name of the substance. Both terms refer to the same pharmacological agent.

Q: Why are people with certain pre-existing conditions advised against Analcid?

Official information indicates that Analcid, like other nonsteroidal anti-inflammatory drugs (NSAIDs), carries recognized risks of serious adverse effects involving the heart, gastrointestinal tract, and kidneys. Patients who have pre-existing conditions related to these organ systems—such as advanced renal disease or active GI bleeding—are identified in regulatory documents as being at higher risk. These conditions are therefore listed in official prescribing information as contraindications or precautions.

Q: Can Analcid be taken if a person has certain kidney conditions?

Analcid is contraindicated—meaning its use is generally restricted—in patients who have severe renal disease or significantly impaired kidney function. For individuals with existing but less severe kidney conditions, official warnings state that caution and monitoring are generally required due to the recognized risk of acute kidney injury associated with this class of medication.

Q: What happens if someone accidentally uses Analcid for a longer period than advised?

Regulatory guidelines explicitly limit the duration of use for Analcid because it is intended for short-term symptom management. The official warnings state that the risks of serious cardiovascular events (like heart attack or stroke) and gastrointestinal bleeding may be dose- and duration-dependent. Therefore, the risk of these serious adverse events is described in warnings as potentially increasing with prolonged use beyond the recommended duration.

Q: Why might the effects of Analcid feel stronger for some people than others?

The body’s response to Analcid can be influenced by various factors described in official labeling. For example, co-administering the drug with certain other medications, specifically CYP2C9 inhibitors, can increase the amount of Analcid in the body's system. Additionally, patients who have underlying liver or kidney impairment may experience the accumulation of the drug and its metabolites, which can influence how the drug's effects are perceived.

Q: Is Analcid available without a prescription in some countries?

In the United States, Mefenamic Acid (Analcid) is available only with a prescription from a healthcare provider. The drug’s availability status is determined by local regulatory authorities.

Q: Is Analcid known to cause drowsiness or affect alertness?

Official safety documents list side effects such as dizziness and fatigue as possible effects of Analcid. Some regulatory documents also note the potential for drowsiness and official information cautions against driving or operating machinery if these effects are experienced.

Q: Are there any specific warnings related to Analcid use and driving?

Official patient information indicates that if central nervous system side effects, such as drowsiness, dizziness, or changes in vision, are experienced, caution should be exercised regarding driving or operating complex machinery. These warnings are related to the potential effects on alertness and coordination.

Q: Is Analcid a medication commonly used for fever?

Mefenamic Acid (Analcid) is classified as a nonsteroidal anti-inflammatory drug (NSAID) and is officially described as possessing analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) properties. The overall utility of the medication is based on these established anti-inflammatory, analgesic, and antipyretic properties.

Q: Does the official information for Analcid mention any risk of dependency?

Official regulatory documents, including those that describe the drug's safety profile and warnings, do not list dependency, abuse, or addiction potential for Analcid.

Q: Is Analcid similar in function to histamine blockers?

Analcid is classified as an NSAID and functions by inhibiting certain enzymes (COX-1 and COX-2) to reduce the production of prostaglandins. This mechanism is different from that of histamine blockers (H2RAs), which act to reduce the secretion of stomach acid.

Q: Are there special considerations for discontinuing the use of Analcid?

Analcid is only approved for short-term use, meaning its discontinuation is an expected part of the treatment process. Because it is not intended for chronic, long-term use, regulatory documents do not specify a controlled tapering or discontinuation regimen.

Q: Has Analcid been studied in older adults?

Although appropriate studies have not demonstrated geriatric-specific problems, official research statements indicate that data regarding the full effects in older adults remains insufficient. For this reason, use in older adults requires caution and restricted duration due to an increased risk of serious adverse events.

Q: Are there foods that should be avoided because they might interact with Analcid?

Official product information advises that Analcid should be taken with food or milk to help with administration. Regulatory information specifically notes that consuming alcohol while using Analcid may increase the risk of serious gastrointestinal bleeding and is typically advised against.

Q: Is it true that Analcid can affect how other medications are absorbed?

Official documentation does state that co-administration with certain antacids, specifically those containing magnesium hydroxide, can significantly increase the rate and amount of Analcid that is absorbed into the body. Interactions affecting the absorption of other medicines by Analcid are not explicitly listed in the regulatory documents.

Q: Do official documents mention any effects of Analcid on bone density?

The drug’s main function is to manage inflammation and pain. Research related to bone has examined its symptomatic control in conditions like osteoarthritis, but official documents do not focus on direct effects on bone mass or density.

How to Store and Dispose of Analcid (Mefenamic Acid)

Official regulatory documents define specific conditions for the storage and disposal of Analcid (Mefenamic Acid).

Storage Requirements

The product must be stored at controlled room temperature, generally defined as not exceeding 25 C (77 F), with protection from excess heat and moisture. To maintain its labeled shelf-life, the medication must be kept in its original container and the container must be kept tightly closed. Freezing the product should be avoided. As a mandatory child-safety measure, the medicine must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired product should be disposed of using an official drug take-back program or mail-back service when available. If those options are not accessible, regulatory guidance permits disposal in the household trash by mixing the medicine with an unappealing substance, sealing it in a plastic bag, and then discarding it.